Toca 511联合Toca FC治疗部分复发高级别胶质瘤患者持久完全缓解
Toca 511是一种研究性γ-逆转录病毒复制载体,联合缓释5-氟胞嘧啶(Toca FC)在临床前可局部产生5-氟尿嘧啶、清除免疫抑制性髓系细胞并诱导抗肿瘤免疫。这项Toca 511剂量递增Ⅰ期试验(NCT01470794)纳入56例标准治疗后复发的HGG患者,术后瘤腔壁注射Toca 511并口服Toca FC周期治疗,观察到持久完全缓解;按Toca 511剂量及Ⅲ期随访入组要求划分的亚组持久缓解率为21.7%,截至2017年8月25日全部缓解者仍维持缓解且存活33.9+至52.2+个月。
要点
- 56例复发高级别胶质瘤患者接受Toca 511瘤腔注射联合口服Toca FC,观察到持久完全缓解。
- 按Toca 511剂量及Ⅲ期入组要求划分的亚组持久缓解率为21.7%,含IDH1突变与野生型肿瘤。
- 截至2017年8月25日全部缓解者仍维持缓解,存活33.9+至52.2+个月。
核心结论
- Ⅰ期试验中复发高级别胶质瘤患者接受Toca 511联合Toca FC治疗后观察到多年持久缓解,该疗法将在随机Ⅲ期试验中进一步评估。
- 首次复发时接受治疗的IDH1突变患者中完全缓解者可能富集。
研究设计与样本
- Toca 511剂量递增Ⅰ期试验(NCT01470794),纳入标准治疗后复发的高级别胶质瘤患者,行手术切除后瘤腔壁注射Toca 511,随后口服Toca FC周期治疗。
- 共56例患者;另按Toca 511剂量及Ⅲ期随访入组要求划分亚组,该亚组包含IDH1突变与野生型肿瘤。
主要发现
- 56例患者中观察到持久完全缓解。
- 按Toca 511剂量及Ⅲ期入组要求划分的亚组持久缓解率为21.7%。
- 缓解者中位随访时间为35.7+个月。
- 截至2017年8月25日,全部缓解者仍维持缓解,且在Toca 511给药后33.9+至52.2+个月仍存活,提示持久缓解与总生存呈正相关。
临床怎么用
- 原文结论为Ⅰ期试验中观察到多年持久缓解,该疗法将在随机Ⅲ期试验中进一步评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months. In this setting, relapse is nearly universal and most responses are transient. METHODS: In this Toca 511 ascending-dose phase I trial (NCT01470794), HGG patients who recurred after standard of care underwent surgical resection and received Toca 511 injected into the resection cavity wall, followed by orally administered cycles of Toca FC. RESULTS: Among 56 patients, durable complete responses were observed. A subgroup was identified based on Toca 511 dose and entry requirements for the follow-up phase III study. In this subgroup, which included both isocitrate dehydrogenase 1 (IDH1) mutant and wild-type tumors, the durable response rate is 21.7%. Median duration of follow-up for responders is 35.7+ months. As of August 25, 2017, all responders remain in response and are alive 33.9+ to 52.2+ months after Toca 511 administration, suggesting a positive association of durable response with overall survival. CONCLUSIONS: Multiyear durable responses have been observed in rHGG patients treated with Toca 511 + Toca FC in a phase I trial, and the treatment will be further evaluated in a randomized phase III trial. Among IDH1 mutant patients treated at first recurrence, there may be an enrichment of complete responders.
引用
- Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018. PMID: 29762717. doi:10.1093/neuonc/noy075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。